Evidence map›Paper›PMID 39809847›Full record

ArticleMolecular psychiatry2025

Neurophysiological correlates of ketamine-induced dissociative state in bipolar disorder: insights from real-world clinical settings.

Claudio Agnorelli, Alessandra Cinti, Giovanni Barillà, Francesco Lomi, Adriano Scoccia, Alberto Benelli, Francesco Neri, Carmelo Luca Smeralda, Alessandro Cuomo, Emiliano Santarnecchi and 5 more

Abstract read
In one paragraph

Article in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Detecting neuroplastic effects induced by ketamine in healthy human subjects: A multimodal approach.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Claudio Agnorelli *Department of Molecular Medicine, Division of Psychiatry, School of Medicine, University of Siena, Siena, Italy. claudioagnorelli96@gmail.com.ORCID 0000-0002-9100-7800
Alessandra Cinti *Siena Brain Investigation and Neuromodulation Lab, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Giovanni BarillàDepartment of Molecular Medicine, Division of Psychiatry, School of Medicine, University of Siena, Siena, Italy.
Francesco LomiSiena Brain Investigation and Neuromodulation Lab, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Adriano ScocciaSiena Brain Investigation and Neuromodulation Lab, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Alberto BenelliSiena Brain Investigation and Neuromodulation Lab, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Francesco NeriSiena Brain Investigation and Neuromodulation Lab, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Carmelo Luca SmeraldaSiena Brain Investigation and Neuromodulation Lab, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Alessandro CuomoDepartment of Molecular Medicine, Division of Psychiatry, School of Medicine, University of Siena, Siena, Italy.
Emiliano SantarnecchiPrecision Neuroscience & Neuromodulation Program, Gordon Center for Medical Imaging, Department of Radiology, Neurology, Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Elisa TattiDepartment of Molecular, Cellular & Biomedical Sciences, CUNY, School of Medicine, New York, NY, USA.
Kate GodfreyCentre for Psychedelic Research, Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK.
Francesca TarantinoUnit of Anesthesia and Neurological Intensive Care, Department of Neurological and Motor Sciences, University of Siena, Siena, Italy.
Andrea FagioliniDepartment of Molecular Medicine, Division of Psychiatry, School of Medicine, University of Siena, Siena, Italy.ORCID 0000-0001-5827-0853
Simone RossiSiena Brain Investigation and Neuromodulation Lab, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.ORCID 0000-0001-6697-9459

Funding

EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 101095436
6 · The paper itself

Abstract

Ketamine, a dissociative compound, shows promise in treating mood disorders, including treatment-resistant depression (TRD) and bipolar disorder (BD). Despite its therapeutic potential, the neurophysiological mechanisms underlying ketamine's effects are not fully understood. This study explored acute neurophysiological changes induced by subanesthetic doses of ketamine in BD patients with depression using electroencephalography (EEG) biomarkers. A cohort of 30 BD (F = 12) inpatients with TRD undergoing ketamine treatment was included in the study. EEG recordings were performed during one of the ketamine infusions with doses ranging from 0.5 to 1 mg/kg, and subjective effects were evaluated using the Clinician-Administered Dissociative States Scale (CADSS). Both rhythmic and arrhythmic features were extrapolated from the EEG signal. Patients who exhibited a clinical response to ketamine treatment within one week were classified as early responders (ER), whereas those who responded later were categorized as late responders (LR). Ketamine reduced low-frequency spectral power density while increasing gamma oscillatory power. Additionally, ketamine flattened the slope of the power spectra, indicating altered scale-free dynamics. Ketamine also increased brain signal entropy, particularly in high-frequency bands. Notably, LR exhibited greater EEG changes compared to ER, suggesting endophenotypic differences in treatment sensitivity. These findings provide valuable insights into the neurophysiological effects of ketamine in BD depression, highlighting the utility of EEG biomarkers for assessing ketamine's therapeutic mechanisms in real-world clinical settings. Understanding the neural correlates of ketamine response may contribute to personalized treatment approaches and improved management of mood disorders.

Indexed as

Bipolar DisorderDissociative DisordersKetamineAdultBrainDepressive Disorder, Treatment-ResistantElectroencephalographyFemaleHumansMaleMiddle AgedKetamine

Identifiers

PMID39809847
PMCPMC12185349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.